ClearPoint Neuro, Inc. (CLPT): Price and Financial Metrics
CLPT Price/Volume Stats
Current price | $7.07 | 52-week high | $10.95 |
Prev. close | $7.15 | 52-week low | $4.05 |
Day low | $6.93 | Volume | 105,500 |
Day high | $7.21 | Avg. volume | 162,417 |
50-day MA | $7.06 | Dividend yield | N/A |
200-day MA | $6.26 | Market Cap | 190.72M |
CLPT Stock Price Chart Interactive Chart >
CLPT POWR Grades
- Sentiment is the dimension where CLPT ranks best; there it ranks ahead of 70.79% of US stocks.
- The strongest trend for CLPT is in Growth, which has been heading up over the past 26 weeks.
- CLPT's current lowest rank is in the Momentum metric (where it is better than 4.37% of US stocks).
CLPT Stock Summary
- With a price/sales ratio of 6.82, CLEARPOINT NEURO INC has a higher such ratio than 84.53% of stocks in our set.
- In terms of twelve month growth in earnings before interest and taxes, CLEARPOINT NEURO INC is reporting a growth rate of 39.46%; that's higher than 79.05% of US stocks.
- In terms of volatility of its share price, CLPT is more volatile than 78.87% of stocks we're observing.
- Stocks that are quantitatively similar to CLPT, based on their financial statements, market capitalization, and price volatility, are NSPR, SERA, TARS, DYAI, and BLZE.
- CLPT's SEC filings can be seen here. And to visit CLEARPOINT NEURO INC's official web site, go to www.clearpointneuro.com.
CLPT Valuation Summary
- In comparison to the median Healthcare stock, CLPT's price/sales ratio is 240.91% higher, now standing at 7.5.
- CLPT's price/sales ratio has moved down 0.4 over the prior 141 months.
Below are key valuation metrics over time for CLPT.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CLPT | 2023-12-29 | 7.5 | 6.9 | -7.7 | -7.1 |
CLPT | 2023-12-28 | 7.8 | 7.2 | -8.0 | -7.4 |
CLPT | 2023-12-27 | 7.7 | 7.1 | -7.8 | -7.3 |
CLPT | 2023-12-26 | 7.3 | 6.8 | -7.5 | -6.9 |
CLPT | 2023-12-22 | 7.2 | 6.7 | -7.4 | -6.8 |
CLPT | 2023-12-21 | 7.3 | 6.8 | -7.5 | -6.9 |
CLPT Growth Metrics
- The 5 year cash and equivalents growth rate now stands at 761.92%.
- Its 5 year price growth rate is now at -50.47%.
- The 2 year net income to common stockholders growth rate now stands at -148.37%.
The table below shows CLPT's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 19.659 | -16.654 | -16.199 |
2022-06-30 | 19.087 | -16.098 | -16.391 |
2022-03-31 | 17.3 | -14.835 | -15.831 |
2021-12-31 | 16.299 | -12.697 | -14.41 |
2021-09-30 | 15.73344 | -11.547 | -11.8429 |
2021-06-30 | 14.67863 | -9.617486 | -9.347127 |
CLPT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CLPT has a Quality Grade of C, ranking ahead of 36.69% of graded US stocks.
- CLPT's asset turnover comes in at 0.297 -- ranking 130th of 186 Medical Equipment stocks.
- ANGO, IVC, and MLSS are the stocks whose asset turnover ratios are most correlated with CLPT.
The table below shows CLPT's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.297 | 0.680 | -0.308 |
2021-03-31 | 0.370 | 0.694 | -0.245 |
2020-12-31 | 0.524 | 0.711 | -0.240 |
2020-09-30 | 0.613 | 0.740 | -0.337 |
2020-06-30 | 0.652 | 0.704 | -0.416 |
2020-03-31 | 0.763 | 0.674 | -0.596 |
CLPT Price Target
For more insight on analysts targets of CLPT, see our CLPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $32.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ClearPoint Neuro, Inc. (CLPT) Company Bio
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for insertion of catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. The company has a license agreements with The Johns Hopkins University; development agreement with Mayo Clinic to design and develop MRI-guided therapies for stroke; and a collaborative license and co-development agreement with Clinical Laserthermia Systems AB. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was founded in 1998 and is headquartered in Irvine, California.
Latest CLPT News From Around the Web
Below are the latest news stories about CLEARPOINT NEURO INC that investors may wish to consider to help them evaluate CLPT as an investment opportunity.
Those who invested in ClearPoint Neuro (NASDAQ:CLPT) five years ago are up 365%Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are... |
7 Solid Small-Caps for 2024 and BeyondSmall-cap stocks are positioned to beat the biggest companies in 2024 as risk tolerance climbs and shares remain undervalued |
Are Investors Undervaluing ClearPoint Neuro, Inc. (NASDAQ:CLPT) By 41%?Key Insights The projected fair value for ClearPoint Neuro is US$10.08 based on 2 Stage Free Cash Flow to Equity... |
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2023 Earnings Call TranscriptClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2023 Earnings Call Transcript November 9, 2023 ClearPoint Neuro, Inc. beats earnings expectations. Reported EPS is $-0.0002, expectations were $-0.25. Operator: Thank you for standing by, and welcome to the ClearPoint Neuro, Inc. Q3 2023 Earnings Conference Call. Comments made on this call may include statements that are forward-looking within […] |
ClearPoint Neuro Reports Third Quarter 2023 ResultsBiologics & Drug Delivery Growing 55%; Q3 Operational Cash Burn of $1.8MSOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2023. Third Quarter Highlights Reported quarterly revenue of $5.8 million, a 12% year-over-year increase;Increased biologics and drug delivery revenue |
CLPT Price Returns
1-mo | -3.42% |
3-mo | 10.12% |
6-mo | 38.36% |
1-year | -3.55% |
3-year | -64.69% |
5-year | 114.24% |
YTD | 4.12% |
2023 | -19.83% |
2022 | -24.51% |
2021 | -29.39% |
2020 | 231.04% |
2019 | 205.73% |
Loading social stream, please wait...